Roberts Zachary's Form 4 filing
Allogene Therapeutics, Inc. (ALLO) · filed Feb 4, 2026
- Accession no.
- 0001737287-26-000002
- Filed
- Feb 4, 2026
- Trade date
- Feb 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $63.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Roberts ZacharyCIK 0001851044 | Officer (EVP of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | SSaleDisposed | −35,700 | $1.77 | −$63,189 | 581,166 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +718,763 | $0.00 | $0 | 718,763 | Direct | |
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +203,307 | $0.00 | $0 | 203,307 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.